Long Chain Omega-3 and CVD
It has been speculated that LC Omega-3 is being associated with a reduction of heart arrhythmia, however; new findings have proven such fact is mistaken. The 2016 update of 2004 Agency for Healthcare Research and Quality's evidence review, a comprehensive report evaluated 61 randomized controlled trials (primarily in people with CVD or at risk of CVD) and 37 observational studies (primarily in healthy people), confirmed that effects of marine oil supplements on intermediate CVD outcomes remain largely unchanged. The only observational evidence is observed is that an increase in high-density lipoprotein and low-density lipoprotein cholesterol concentrations. So, the strong effect of marine oils is mainly on triglyceride concentrations.
Possible conflicting findings:
According to the National Institute for Health (NIH), the possible reasons can be due to the fact that findings from the clinical trials and present one have conflicted with each other in addition the public health messaging touting for the benefits of LC Omega-3 on improving the conditions of CVD. For example, the authors of a review prepared by the Tufts Medical Center Evidence-based Practice Center on the effects of EPA and DHA on mortality concluded that mean intakes of up to 200 mg/day are associated with a reduced risk of cardiac, cardiovascular, or sudden cardiac death, but higher intakes do not reduce risk any further. The use of statins for patients with pre-existing conditions of CVD may lead to the conciliations of the findings too.
The bottom line of these findings concluded by The 2015–2020 Dietary Guidelines for Americans is that based on the cohort and observational trials 2 servings a week of seafood provide 250mg of omega-3 fatty acids needed for the prevention of CVD. Taking supplements will provide hardly noticeable changes unless there is deficiency is present.
Sources: National Institue for Health (NIH).gov, Agency for Healthcare and Research review
Comments